FDA pulls authorization for COVID antibody treatment over lack of effectiveness

Evusheld, the preventative monoclonal antibody treatment for COVID-19, has lost its emergency use authorization in the U.S. as it is most likely not effective against the strains of the coronavirus currently circulating. The announcement from the Food and Drug Administration (FDA) comes weeks…#evusheld #fda #astrazeneca #molnupiravir
Source: Reuters: Health - Category: Consumer Health News Source Type: news